Reconstruction

Women with a higher body mass index have a higher risk of complications after flap breast reconstruction.

Even though the surgery is more complex, women are more satisfied with their breasts if they have reconstruction using their own tissue.

The number of U.S. cases of breast anaplastic large-cell lymphoma — a rare cancer linked to textured implants — may be twice as high as U.S. Food and Drug Administration estimates.

Nearly 75% of women surveyed who opted for mastectomy without reconstruction were satisfied with the results, but almost 25% said their decision to go flat was not supported by their surgeons.

A small study found that women who had textured implants for reconstruction after breast cancer surgery had a small but statistically significant increase in the risk of the breast cancer coming back.

The early weeks of the COVID-19 pandemic caused 44% of breast cancer survivors to have a delay in care, according to an online survey.

On July 24, 2019, Allergan announced a global recall of Biocell textured breast implants and tissue expanders after the FDA requested the action.

The FDA has sent warning letters to two breast implant manufacturers because the companies have not conducted the post-approval long-term safety studies that were required as part of the implants' FDA approval.

National Comprehensive Cancer Network treatment guidelines have been developed for breast implant-associated anaplastic large-cell lymphoma, a rare type of cancer linked to textured breast implants.

Compared to DIEP flap reconstruction and implant reconstruction, latissimus dorsi flap reconstruction caused the greatest loss of shoulder function, strength, and mobility.

A study suggests fat grafting breast reconstruction does not increase the risk of breast cancer recurrence compared to more traditional reconstruction techniques.

A study suggests that silicone breast implants are associated with a higher risk of certain autoimmune disorders, as well as stillbirth and melanoma, but the FDA disagrees with the results.

Decisions about the type of reconstruction a woman has should be personalized to each woman's unique situation and informed by the most current information on long-term outcomes, satisfaction, and complication rates.

A Dutch study estimates that for every 7,000 women who get breast implants, one woman will develop anaplastic large-cell lymphoma in the breast by age 75.

White women are 24% more likely to have immediate reconstruction than Black women; 26% more likely than Asian, Pacific Islander, and Native American women; and 19% more likely than Hispanic women.

Rates of breast reconstruction after mastectomy rose 62% from 2009 to 2014.

A very small study suggests that more than half of women who had mastectomy made a reconstruction decision that didn't align with their goals and preferences.

A study suggests that 1 year after surgery, women who had immediate autologous reconstruction were more satisfied with their breasts than women who had immediate implant reconstruction. Still, women who had autologous reconstruction had more pain than they did before surgery.

Women with breast implants have a very low but increased risk of developing anaplastic large-cell lymphoma compared to women who do not have breast implants.

A study suggests that radiation after implant reconstruction seems to cause more complications than radiation given after autologous reconstruction.

Older and younger women benefit equally from breast reconstruction; age shouldn't disqualify a woman from having reconstruction.

Women who have lipofilling after reconstruction are no more likely to have a recurrence or be diagnosed with a new cancer than women who never had lipofilling.

The most effective treatment for implant-associated ALCL is surgically removing the implant and surrounding tissue capsule.

Doing a full breast lift after autologous reconstruction may allow women with large or sagging breasts to have nipple-sparing mastectomy.